Intervention

Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions1

Lead sponsors shown1

Clinical trials

2 shown

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerNCT06355037 · 2024-05-20

Inosine Reverse Chemo Resistance in Triple Negative Breast CancerNCT06355024 · 2024-05-11

Common conditions

Triple-negative Breast Cancer2

Leading sponsors

Fudan University2

Trial status mix

COMPLETED1

UNKNOWN1

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.